Research progress on the treatment of bullous pemphigoid with Dupilumab

Abstract

In recent years, there have been many reports on the use of Dupilumab in the treatment of bullous pemphigoid. Dupilumab specifically binds to the subunit alpha of interleukin 4 receptor (IL-4Rα), blocking the signal transduction of interleukin (IL)-4 and IL-13, inhibiting the proliferation of B cells, reducing the recruitment of eosinophils, and suppressing the function of Th2-related chemotactic factors, thereby improving skin lesions and itching of patients. This article reviews the potential mechanisms, clinical efficacy, and adverse reactions of Dupilumab in the treatment of bullous pemphigoid.

Keywords

• bullous pemphigoid
• treatment
• dupilumab